We have located links that may give you full text access.
ENGLISH ABSTRACT
JOURNAL ARTICLE
[Possibilities and limits of chemotherapy of diseases caused by herpes simplex and varicella-zoster virus].
The available antiviral chemotherapeutic agents for the treatment of herpes simplex type 1 and 2 and varicella zoster virus infections are discussed in respect of their mechanism of action, clinical effects, and side effects. Although effective under experimental conditions most of the antiherpetic drugs need further evaluation of clinical efficacy in controlled trials. It is possible to reduce initial herpetic pain mainly in patients with zoster by topical application of 5% 5-iodo-2'-deoxyuridine solved in dimethylsulphoxide when treatment starts within the first 3 days of blister eruption. The postzosteric neuralgia is not influenced. A shortening of pain seems also possible in primary herpes simplex virus type 2 infection. For recurrent herpes simplex there is no proven effect on duration or frequency of recurrences with available antiherpetic drugs. The indication for antiviral chemotherapy is limited not only by the unpredictable, mainly self-limited, course of herpes simplex and zoster but also by the possible side effects of chemotherapeutic agents. Severe and life-threatening herpes disease, e.g., in immunosuppressed patients or newborns, can be defeated with vidarabin applied i.v. and, in the near future, with acyclovir.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app